IN SAFE HANDS.EVERY STEP OF THE WAY.REAL WORLD EVIDENCE SOLUTIONS

DELIVERING LONG-TERM SUCCESS BY UNLOCKING THE COMPLETE VALUE OF YOUR HEALTHCARE PRODUCT ACROSS ITS FULL LIFECYCLE

Whether your company is looking to meet regulatory requirements, realize the broadest market access, or achieve optimal post-launch value for your product:

+ Kantar offers trusted evidence experts with the most comprehensive databases across the globe

+ We are one company that delivers full in-house service from start to finish – with no outsourcing

ADVANCING HEALTHCARE AND DRIVING BETTER PATIENT OUTCOMESIt’s all about the patient – always has been, always will be. Everything we do as members of the healthcare community is about improving people’s lives daily by working to make the world a healthier place.

However, in this fruitful age of life-changing innovation, the need for trusted market access and real-world research (RWR) has never been greater, as the healthcare industry faces increasing challenges relating to clinical outcomes, risk and safety, and pricing and access.

Kantar is one company that can meet these challenges head-on. We provide integrated research and outcomes

KANTAR REAL-WORLD EVIDENCE SOLUTIONS

WE UNDERSTAND THE IMPORTANCE OF VALUE CREATION

VALUEQUANTIFICATION

VALUECOMMUNICATION

VALUEIDENTIFICATION

solutions, as well as full in-house service, from pre-launch to post-marketing activities. With a unique combination of broad, global, scientific expertise, backed by operational infrastructure, we fully execute all field work and analyze, publish and communicate all of the data we generate. In addition to industry-leading databases, we offer proprietary study protocols and extensive experience with systematic literature reviews.

In short, we’re proud to offer decades of experience in pre- and post-approval clinical research studies. This allows us to be fully adaptive when realizing your product’s value.

+ Unique access to proprietary databases such as the National Health and Wellness Survey (NHWS) combined with integrated EHR, EMR, chart audit and claims data solutions.

+ Strong scientific heritage with experienced staff worldwide in RWR, clinical research, and oncology and other chronic diseases

+ Over 1,500 published pieces from 400 conferences and journals

+ Outstanding expertise in KOL identification and scientific advisory board management

+ Excellent track record in ethical committee compliance for interventional and non-interventional studies (member of EUCROF – European CRO Federation)

+ Presence in 80+ countries to provide evidence generation support, including capabilities in South America

+ Broad access to an extensive real-world panel of physicians, patients, consumers, nurses, pharmacists, caregivers, KOLs and payers

OUR STRENGTHS

ABOUT KANTAR

ABOUT ZEG BERLIN

Kantar is the world’s leading data, insights and consulting company. We understand more about how people think, feel, shop, share, vote and view than anyone else. Combining our expertise in human understanding with advanced technologies, Kantar’s 30,000 people help the world’s leading organizations succeed and grow.

For more information, please contact info@kantarhealth.com, or visit us at www.kantar.com/health

Founded in 1990, ZEG Berlin (Center for Epidemiology and Health Research) is an independent research institute and pioneer in the field of pharmacoepidemiology. It focuses on pharmacoepidemiology and outcomes research, particularly on drug safety and risk management and minimization, and specializes in large multinational observational studies. ZEG is affiliated with Kantar. For more information, please visit www.zeg-berlin.de.

Kantar is a world-class evidence specialist with proprietary databases spanning the globe. Whether your need originates from market access, regulatory/medical affairs, pharmacovigilance or health economics and outcomes research, we can help you generate evidence to support the success of your product through its lifecycle.

+ Global network of patient-level datasets + Health economics and outcomes research + Strategic market access + Clinical trials and late-phase studies + Risk management and pharmacoepidemiology + Systematic literature reviews